The Liver and COVID‐19 in Mexico

Remes-Troche, José María; Velasco, J.A. Velarde-Ruiz

doi:10.1002/cld.1153

Cited by 4 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Mexico, as in other parts of the world, the desperation for effective therapy at the beginning of the pandemic led to the indiscriminate and irrational use of drugs that could potentially trigger DILI. It is probable that many of the abnormal LFT in our Mexican patients were associated with the following drugs: hydroxychloroquine, ivermectin, dexamethasone, azithromycin, lopinavir/ritonavir, baricitinib, tocilizumab and remdesivir 40 .…”

Section: Drug-induced Liver Injury (Dili) and Covid-19mentioning

confidence: 98%

Impacto de COVID-19 en enfermedad hepatica pre-existente

Abdo-Francis,

Moreno-Alcantar,

Pérez-Hernández

et al. 2024

CIRU

View full text Add to dashboard Cite

Patients with chronic liver disease of any etiology who become infected with SARS-CoV-2 have been found to have a higher risk of mortality compared to those patients who do not have chronic liver disease. A literature review was conducted in the relationship between COVID 19 and preexistence of liver disease. The proportion of COVID-19 patients with abnormal liver function on admission ranged from 40 % to 75 % and the proportion with liver injury was close to 30%. Current studies show an important association between preexisting liver disease and COVID-19. The presence of cirrhosis is now an independent predictor of severity for COVID-19 and prolonged hospitalization in this group of patients. Patients with cirrhosis have a higher mortality rate, and this rate rises with increasing severity.

show abstract

Section: Drug-induced Liver Injury (Dili) and Covid-19mentioning

confidence: 98%

Impacto de COVID-19 en enfermedad hepatica pre-existente

Abdo-Francis,

Moreno-Alcantar,

Pérez-Hernández

et al. 2024

CIRU

View full text Add to dashboard Cite

show abstract

Agreement Between the Rapid Antigen Test for SARS-CoV-2 and the RT-qPCR Diagnostic Test

Barrios-Pérez,

Cid-Oros,

Becerril-Gutiérrez

et al. 2024

Atención Familiar

View full text Add to dashboard Cite

Objective: to assess the agreement between the rapid antigen testing (RATs) for SARS-CoV-2 and quantitative reverse transcription polymerase chain reaction (RT-qPCR). Methods: analytical CROSS-sectional study, conducted in three medical units from January 1, 2021, to June 30, 2022, in Mexico City, Mexico. Non-probabilistic sampling was performed using data from the Online Notification System for Epidemiological Surveillance. Data analysis was performed using frequency measures, Cohen’s kappa index, and maximum likelihood estimation. Results: Of 2173 participants with both diagnostic tests: 565 respiratory samples were concordant with a positive result (26.09% CI95% 24.25 - 27.99%), and 1229 with a negative result (56.55% CI95% 54.44 - 58.65%). The sensitivity of RAT VERSUS RT-qPCR was estimated to be 65.17% (95%CI 61.99 - 68.33%), while the specificity was 94.10% (95%CI 92.82 - 95.38%); a positive predictive value of 88.01% (95%CI 85.23 - 90.41%), and a negative predictive value of 80.27% (95%CI 78.19 - 82.24%). The Cohen’s kappa index was 0.62 (substantial agreement), and a calculated likelihood ratio of 40% at pre-test prevalence, a post-test probability of 88.3% was observed for a positive result with RAT in case of having COVID-19. Conclusion: The present study demonstrated substantial concordance between RAT and RT-qPCR, supporting the feasibility of using both tests. This provides clinicians with a valuable tool for informed decision making in the diagnostic context of COVID-19.

show abstract

Concordancia entre la prueba de antígenos rápida para SARS-CoV-2 y la prueba diagnóstica de RT-qPCR

Barrios-Pérez,

Cid-Oros,

Becerril-Gutiérrez

et al. 2024

Atención Familiar

View full text Add to dashboard Cite

Objetivo: estimar la concordancia de la prueba de antígenos rápida (PAR) para SARS-CoV-2 y la prueba de reacción en cadena de la polimerasa cuantitativa con transcripción inversa (RT-qPCR). Métodos: estudio transversal analítico, realizado en tres unidades médicas del 1 de enero de 2021 al 30 de junio de 2022 en la Ciudad de México, México. Se realizó muestreo no probabilístico utilizando los datos del Sistema de Notificación en Línea para la Vigilancia Epidemiológica. El análisis de datos se realizó con medidas de frecuencia, índice de kappa de Cohen e índice de máxima verosimilitud. Resultados: de 2173 participantes con ambas pruebas diagnósticas: 565 muestras respiratorias fueron concordantes con resultado positivo (26.09% IC95% 24.25 – 27.99%) y 1229 con resultado negativo (56.55% IC95% 54.44 – 58.65%). Se estimó que la sensibilidad de la par frente a RT-qPCR fue de 65.17% (IC95% 61.99 – 68.33%) mientras que la especificidad fue de 94.10% (IC 95% 92.82 – 95.38%); un valor predictivo positivo de 88.01% (IC95% 85.23 – 90.41%) y valor predictivo negativo de 80.27% (IC95% 78.19 – 82.24%). El índice de kappa de Cohen fue de 0.62 (concordancia sustancial) y una razón de verosimilitud calculada de 40% ante una prevalencia preprueba, se observó una probabilidad posprueba del 88.3% para un resultado positivo con PAR en caso de tener la COVID-19. Conclusión: el presente estudio reveló una concordancia sustancial entre PAR y RT-qPCR, lo que respalda la viabilidad del uso de ambas pruebas. Esto proporciona a los clínicos una herramienta valiosa para la toma de decisiones informadas en el contexto diagnóstico de la COVID-19.

show abstract

The Liver and COVID‐19 in Mexico

Abstract: Content available: Author Interview and Audio Recording

Cited by 4 publications

References 13 publications

Impacto de COVID-19 en enfermedad hepatica pre-existente

Impacto de COVID-19 en enfermedad hepatica pre-existente

Agreement Between the Rapid Antigen Test for SARS-CoV-2 and the RT-qPCR Diagnostic Test

Concordancia entre la prueba de antígenos rápida para SARS-CoV-2 y la prueba diagnóstica de RT-qPCR

Contact Info

Product

Resources

About